Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

440
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

368
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
Obesity01:24

Obesity

1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.9K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying Predictors of Weight-Related Outcomes With Fixed-Dose, Extended-Release Naltrexone and Bupropion Among Treatment-Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis.

Obesity science & practice·2026
Same author

GLP-1 and Nutrient Stimulated Hormone Targets: Beyond Weight Loss.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026
Same author

TOS/OMA/OAC Expert Guidance Statement on Obesity Pharmacotherapy: A Humbling Call to Action.

Obesity (Silver Spring, Md.)·2026
Same author

Clinical and Preclinical Obesity in Korean Adults from 2014 to 2023.

Diabetes & metabolism journal·2026
Same author

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.

JAMA cardiology·2025
Same author

Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply.

The New England journal of medicine·2025

Related Experiment Video

Updated: May 2, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K

Update on obesity pharmacotherapy.

George A Bray1, Donna H Ryan

  • 1Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana.

Annals of the New York Academy of Sciences
|March 20, 2014
PubMed
Summary

Two drug categories manage obesity: those for obesity itself and those for chronic conditions. Effective weight management involves selecting appropriate medications based on individual patient needs and treatment goals.

Keywords:
exenatideliraglutidelorcaserinmetforminobesityorlistatoverweightphenterminetopiramateweight loss

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.8K
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.3K

Related Experiment Videos

Last Updated: May 2, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.8K
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.3K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Obesity Medicine

Background:

  • Obesity management involves two main drug classes: those targeting obesity directly and those impacting weight in patients with comorbid chronic diseases.
  • Medications for obesity per se include long-term and short-term treatment options, each with specific mechanisms and efficacy.
  • Weight-influencing medications are also prescribed for chronic conditions like diabetes, depression, and psychiatric disorders.

Purpose of the Study:

  • To review and categorize approved drug therapies for obesity management.
  • To discuss the efficacy and limitations of various anti-obesity medications.
  • To highlight the role of weight-influencing drugs in managing chronic diseases in obese patients.

Main Methods:

  • Review of approved pharmacological treatments for obesity.
  • Analysis of drug mechanisms, weight loss efficacy, and side effect profiles.
  • Consideration of drug selection for patients with obesity and co-existing chronic conditions.

Main Results:

  • Orlistat (5-8 kg weight loss) inhibits fat digestion but causes gastrointestinal issues.
  • Lorcaserin (4-7 kg weight loss) is a serotonin-2C agonist with fewer side effects.
  • Phentermine/topiramate (8-10 kg weight loss) requires pregnancy screening.
  • Short-term options include sympathomimetics like phentermine.
  • For chronic diseases, drugs that promote weight loss alongside disease management are preferred.

Conclusions:

  • Treatment failure (less than 3% body weight loss in 3 months) necessitates reevaluation of obesity medication.
  • Optimal drug selection for obesity requires considering individual patient profiles, comorbidities, and treatment objectives.
  • Weight-centric prescribing for chronic diseases can improve overall patient outcomes by addressing multiple health concerns simultaneously.